Rogers Corp (ROG)

115.21
2.98 2.52
NYSE : Technology
Prev Close 118.19
Open 119.09
Day Low/High 112.29 / 119.09
52 Wk Low/High 51.98 / 119.46
Volume 86.36K
Avg Volume 115.30K
Exchange NYSE
Shares Outstanding 18.13M
Market Cap 2.14B
EPS 2.70
P/E Ratio 35.77
Div & Yield N.A. (N.A)

Latest News

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

- AVENIO Millisect System utilizes an automated, digitally assisted process to reliably and efficiently isolate clinically relevant cells for diagnostic testing

Rogers Schedules Second Quarter 2017 Earnings Call For August 1

Rogers Schedules Second Quarter 2017 Earnings Call For August 1

Rogers Corporation (NYSE:ROG) plans to announce second quarter 2017 results on July 31 after market close, which will be followed by a conference call on August 1 at 9am ET.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

Rogers To Participate In CJS Summer Conference

Rogers To Participate In CJS Summer Conference

Rogers Corporation (NYSE:ROG) today announced Senior Vice President and CTO, Bob Daigle, will be presenting at the CJS Summer Conference in New York on Tuesday, July 11 at 8:00 am EDT.

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from HAVEN 1, a Phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and...

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Roche Expands Harmony® Prenatal Test To Include 22q11.2 Deletion Testing

-- New test option will be available globally mid-2017 in the Harmony CE-IVD kit and through the test send-out service from Ariosa Diagnostics Inc.

Genentech's Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III...

Roche Receives FDA Approval For Fourth-generation HIV Combination Antigen-antibody Assay --allowing Detection Of Infection With High Sensitivity And Specificity

Elecsys® HIV combi PT assay demonstrates commitment to improving efficiency by aiding labs in consolidating testing with other routine immunoassays

New Data At EAN Show Genentech's Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new post-hoc analyses from the OCREVUS TM (ocrelizumab) Phase III clinical trial program in people with relapsing and primary...

FDA Approves RITUXAN HYCELA (Rituximab And Hyaluronidase Human) For Subcutaneous Injection In Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Save The Date: Rogers To Host Investor Day August 17

Rogers Corporation (NYSE:ROG) Save the Date. Rogers Corporation plans to host an investor day the morning of August 17 at the New York Stock Exchange.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

APHINITY Study Shows Genentech's Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III...

Phase III Study Showed Genentech's Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III ALEX study showed Alecensa ® (alectinib) significantly reduced the risk of disease worsening or death...

Rogers To Participate In B. Riley & Co. Annual Investor Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, and Senior Vice President and CFO, Janice Stipp, will be presenting at the B.

FDA Approves Genentech's Actemra (Tocilizumab) For Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Rogers To Participate In Houlihan Lokey Global Industrial Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, and Senior Vice President and CFO, Janice Stipp, will be presenting at the Houlihan Lokey Global Industrial Conference in New York City...

Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

Roche Receives FDA Approval For Complementary PD-L1 (SP263) Biomarker Test In Urothelial Carcinoma

- Urothelial carcinoma, the most common type of bladder cancer, is the fourth most common cancer in men in the United States[1]

FDA Clears Roche High-volume Immunoassay Lab Testing Solution To Support Critical Medical Treatment Decisions

cobas® e 801 module delivers on the promise of next-generation laboratory efficiency

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

ROG Crosses Above Average Analyst Target

In recent trading, shares of Rogers Corp. have crossed above the average analyst 12-month target price of $92.33, changing hands for $92.47/share.

Rogers Corporation Reports First Quarter 2017 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2017 first quarter.

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programs will be presented during the 69th American Academy of...

Rogers Schedules First Quarter 2017 Earnings Call For April 27

Rogers Corporation (NYSE:ROG) plans to announce first quarter 2017 results on April 26 after market close, which will be followed by a conference call on April 27 at 9am ET.